Vienna-based biotech company Marinomed on a growth path
Vienna-based Marinomed Biotech AG (Marinomed) continues its growth path. The company is making significant progress in developing its Marinosolv® technology platform and can start a Phase III clinical approval study for the first product derived from the technology platform earlier than expected, still in winter 2018/19.
(firmenpresse) -
Vienna, August 29, 2018. Vienna-based Marinomed Biotech AG (Marinomed) continues its growth path. The company is making significant progress in developing its Marinosolvral infections of the respiratory tract, the biopharmaceutical company was able to expand its sales territory by ten markets with the conclusion of two new contracts. Marinomed is therefore evaluating several options for financing the continued development of the company, including an IPO on the Vienna Stock Exchange.
INNOVATIVE PLATFORMS TARGETING A MULTIPLE BILLION EURO MARKET
The technology platform Marinosolv
The allergic rhinitis market is a multiple billion Euro market with strong growth prospects. Marinomed intends to tap into this market with its Marinosolv
According to the World Allergy Organization (WAO), up to 30% of the world
TEN ADDITIONAL MARKETS FOR CARRAGELOSE
Marinomed has also seen positive development for its already established and successful Carrageloseps. Berlin-Chemie has been commercializing Marinomed products already in three countries since 2016. Marinomed
In addition to the extended partnership agreements with Berlin-Chemie and Mundipharma, Marinomed has already ventured into markets such as China, Saudi Arabia and Australia this year. Through these global distribution partnerships, Marinomed''s Carrageloseperform 65 product launches since 2008.
About Marinomed Biotech AG
Marinomed is a Vienna based biopharmaceutical company focusing on the development of innovative products derived from patent protected technology platforms to treat respiratory and ophthalmic conditions. The Carragelosetechnology platform increases the efficacy of hardly soluble compounds for the treatment of sensitive tissues such as the eyes and nose. Further information is available at www.marinomed.com.
Enquiries:
Dr Eva Prieschl-Grassauer
Chief Scientific Officer, Marinomed
Veterin
Tel.: +43 (0)1 250 77 4460
E-mail: eva.prieschl(at)marinomed.com
http://www.marinomed.com
Roland Mayrl
Managing Partner, Metrum Communications
Prinz-Eugen-Stra
Tel.: +43 (0) 1 504 69 87 331
E-mail: r.mayrl(at)metrum.at
http://www.metrum.at
Themen in dieser Pressemitteilung:
Unternehmensinformation / Kurzprofil:
Increased awareness for Science & Research & Education. In Austria and around the world. That is our mission.
Datum: 29.08.2018 - 09:04 Uhr
Sprache: Deutsch
News-ID 1540320
Anzahl Zeichen: 6008
contact information:
Contact person: Till C. Jelitto
Town:
Vienna
Phone: +43 1 505 70 44
Kategorie:
Research & Development
Typ of Press Release: Erfolgsprojekt
type of sending: Veröffentlichung
Date of sending: 29.08.2018
Anmerkungen:
Diese Pressemitteilung wurde bisher 486 mal aufgerufen.
Die Pressemitteilung mit dem Titel:
"Vienna-based biotech company Marinomed on a growth path
"
steht unter der journalistisch-redaktionellen Verantwortung von
PR&D - Public Relations for Research & Education (Nachricht senden)
Beachten Sie bitte die weiteren Informationen zum Haftungsauschluß (gemäß TMG - TeleMedianGesetz) und dem Datenschutz (gemäß der DSGVO).
